Jan 27 (Reuters) - Centers for Medicare & Medicaid Services $(CMS)$:
CMS ANNOUNCES SELECTION OF DRUGS FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM
CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE REXULTI, TRULICITY, VERZENIO, XELJANZ; XELJANZ XR AND XOLAIR
CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE ENTYVIO, ERLEADA, KISQALI ,LENVIMA, ORENCIA
CMS: SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATIONS ARE ANORO ELLIPTA, BIKTARVY, BOTOX; BOTOX COSMETIC, CIMZIA, COSENTYX
CMS: DRUG TRADJENTA CHOSEN FOR RENEGOTIATION FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM
CMS-ANY NEGOTIATED & RENEGOTIATED DRUG PRICES OF SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION PROGRAM TO BECOME EFFECTIVE IN 2028
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))